During the Lymphoma Hub Steering Committee meeting, Grzegorz Nowakowski, the Mayo Clinic, Rochester, US, chaired a discussion on anti-CD19 monoclonal antibodies for the treatment of DLBCL.
This discussion also featured Gilles Salles, Sonali Smith, Ulrich Jäger, Catherine Thieblemont, Michael Dickinson, Francesc Bosch, Miles Prince, and Marek Trněný.
Prior to the discussion, Nowakowski presented an overview of tafasitamab (Tafa), a CD19 monoclonal antibody, for the treatment of diffuse large B-cell lymphoma (DLBCL). He highlighted its mechanism of action and discussed the rationale for combining it with lenalidomide (Len) to improve immune-mediated antitumor activity. He reviewed data from the L-MIND trial, where Tafa-Len combination demonstrated a high overall response rate and durable remissions in relapsed/refractory (R/R) DLBCL. He also summarized real-world evidence showing consistent efficacy in patients meeting L-MIND eligibility criteria. Additional insights included the feasibility of using Tafa-Len prior to chimeric antigen receptor (CAR) T-cell therapy, the preservation of CD19 expression post-exposure, and the ongoing FrontMIND trial evaluating Tafa-Len + rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) in previously untreated high-risk DLBCL.
This educational resource is independently supported by Incyte. All content was developed by SES in collaboration with an expert steering committee; funders were allowed no influence on the content of this resource.
","author_name":"Scientific Education Support"}